Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Analysts give Perspective Therapeutics, Inc. (NYSE:CATX) a consensus rating of "Buy", with an average 12-month target price of $12.56.
• Institutional investors have increased their stakes in the company, with hedge funds owning 54.66% of the stock.
• Despite the positive recommendations, Perspective Therapeutics’ stock is currently down 2.6%, trading at $3.82 per share.

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been given an average recommendation of "Buy" by the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $12.5556.

CATX has been the subject of several research reports. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Monday, June 23rd. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Truist Financial dropped their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. B. Riley restated a "buy" rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their price target for the stock from $15.00 to $16.00 in a research note on Tuesday, June 3rd.

Perspective Therapeutics Stock Up 1.4%

Perspective Therapeutics stock traded up $0.05 during trading on Thursday, hitting $3.68. The company had a trading volume of 371,049 shares, compared to its average volume of 952,907. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $16.55. The company's 50 day simple moving average is $3.68 and its 200-day simple moving average is $2.96.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CATX. National Bank of Canada FI grew its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after purchasing an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth $51,000. Ground Swell Capital LLC acquired a new position in shares of Perspective Therapeutics during the second quarter worth $56,000. Finally, Corton Capital Inc. acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth $61,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.